SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics -- Ignore unavailable to you. Want to Upgrade?

To: CCS648 who wrote (827)1/15/2025 3:53:29 PM
From: Redman12341 Recommendation

Recommended By
CCS648

  Respond to of 1230
 
I shouldn’t think so? Seems like the need for a P3. While the complete response rate is good at 9 months what is the drop off over a longer period of time? Anktiva duration is 47 months and ongoing as a comparison which handily beats Adstiladrin (9.7 months) and Pembrolizumab (16.2 months). Don’t forget IBCG is also currently in clinical trials across Europe and should better Anktiva results.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News